223786-53-6

Basic information

• Product Name: 1-(4-NITROPHENYL)PIPERIDINE-3-CARBOXYLIC ACID
• Synonyms: 1-(4-NITROPHENYL)PIPERIDINE-3-CARBOXYLIC ACID;AKOS B034444;4-Carboxy-1-(4-nitrophenyl)piperidine
• CAS NO: 223786-53-6
• Molecular Formula: C12H14N2O4
• Molecular Weight: 250.25
• Mol File: 223786-53-6.mol
• Article Data: 8

Chemical Properties

• Melting Point: 164-166
• Boiling Point: 484.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.346±0.06 g/cm3(Predicted)
• PKA: 4.49±0.20(Predicted)
• CAS DataBase Reference: 1-(4-NITROPHENYL)PIPERIDINE-3-CARBOXYLIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-NITROPHENYL)PIPERIDINE-3-CARBOXYLIC ACID(223786-53-6)
• EPA Substance Registry System: 1-(4-NITROPHENYL)PIPERIDINE-3-CARBOXYLIC ACID(223786-53-6)

Safety Data

• Hazard Codes: Xi
• HazardClass: IRRITANT
• Hazardous Substances Data: 223786-53-6(Hazardous Substances Data)

Usage

Description

1-(4-Nitrophenyl)piperidine-3-carboxylic acid is a chemical compound with the molecular formula C13H15NO4. It is a piperidine derivative that features a nitrophenyl group and a carboxylic acid group. 1-(4-NITROPHENYL)PIPERIDINE-3-CARBOXYLIC ACID has potential pharmacological and biological applications due to its structural properties, which may allow it to interact with biological systems and influence various biochemical processes. The nitrophenyl group could contribute to its potential pharmaceutical properties, while the piperidine ring and carboxylic acid functionality may affect its solubility and reactivity in biological environments.

Uses

Used in Pharmaceutical Industry:
1-(4-Nitrophenyl)piperidine-3-carboxylic acid is used as a potential pharmaceutical compound for its ability to interact with biological systems. The presence of the nitrophenyl group may endow it with specific pharmacological properties, making it a candidate for the development of new drugs and medical treatments.
Used in Biological Research:
In the field of biological research, 1-(4-Nitrophenyl)piperidine-3-carboxylic acid is used as a tool compound to study the interactions between small molecules and biological targets. Its structural features allow it to be a valuable probe for understanding biochemical processes and for the discovery of novel therapeutic agents.

Upstream product

• 7595-60-0 methyl 1-(4-nitrophenyl)piperidine-4-carboxylate 
• 2971-79-1 isonipecotic acid methyl ester 
• 350-46-9 4-Fluoronitrobenzene 
• 1126-09-6 4-carbethoxypiperidine 
• 100-00-5 4-chlorobenzonitrile 
• 216985-30-7 ethyl 1-(4-Nitrophenyl)-4-piperidine carboxylate 
• 498-94-2 isonipecotic acid 

Relevant articles and documents

COMPOUNDS FOR TREATMENT OF INFLAMMATORY DISEASES

The present invention refers to relates to compound for treating inflammatory diseases, said formula I compounds represented, such as, a pharmaceutically acceptable salts, or their, or a hydrate thereof is characterized in that the, polymerized. According to the present invention, interacting with-path 5-LOX a compound or interference, in particular 5- oh height[...]width it recovers sourly, in sacrifice, which display inhibitory effects can be provides compounds having. (by machine translation)

Synthesis and biological evaluation of direct thrombin inhibitors bearing 4-(piperidin-1-yl)pyridine at the P1 position with potent anticoagulant activity

The design and synthesis of a new class of nonpeptide direct thrombin inhibitors, built on the structure of 1-(pyridin-4-yl)piperidine-4-carboxamide, are described. Starting from a strongly basic 1-amidinopiperidine derivative (6) showing poor thrombin (fIIa) and factor Xa (fXa) inhibition activities, anti-fIIa activity and artificial membrane permeability were considerably improved by optimizing the basic P1 and the X-substituted phenyl P4 binding moieties. Structure-activity relationship studies, usefully complemented with molecular modeling results, led us to identify compound 13b, which showed excellent fIIa inhibition (Ki = 6 nM), weak anti-Xa activity (K i = 5.64 μM), and remarkable selectivity over other serine proteases (e.g., trypsin). Compound 13b showed in vitro anticoagulant activity in the low micromolar range and significant membrane permeability. In mice (ex vivo), 13b demonstrated anticoagulant effects at 2 h after oral dosing (100 mg·kg-1), with a significant 43% prolongation of the activated partial thromboplastin time (aPTT), over controls (P 0.05).

PIPERAZINE COMPOUND CAPABLE OF INHIBITING PROSTAGLANDIN D SYNTHASE

This invention relates to a piperazine compound represented by Formula (I), wherein R1 is C1-6 alkyl;R2 is hydroxy, C1-6 alkyl that may have one or more substituents, —(C═O)—N(R3)(R4), or —(C═O)—OR5;R3 and R4 are the same or different, and each represents hydrogen or C1-6 alkyl that may have one or more substituents, orR3 and R4, taken together with a nitrogen atom to which R3 and R4 are attached, may form a saturated heterocyclic group;R5 is hydrogen or C1-6 alkyl that may have one or more substituents; andn is 1 or 2;or a salt thereof.